RSV Seasonal Vaccine Introduction and Growth Strategy
Strong momentum supports confidence in short, medium
and long-term commitments to profitable growth
Full-year 2023 guidance¹
2021-2026 outlook
2031 ambition
Sales growth
8-10%
Adj. operating profit growth
11-13%
Adj. EPS growth
14-17%
GSK
Sales CAGR
>5%
Adj. operating profit CAGR
>10%
Sales
>£33 billion
Growth rates are at constant exchange rates (CER). All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q2 2023 earnings
release and the 2022 Annual Report. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates.
CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID
therapeutic and vaccine solutions are excluded from the above 1. Excluding COVID-19 solutions
7View entire presentation